Leksum's EVs Show Promise in Reducing MV-Related Lung Injury Risks
Leksum LLC's study reveals extracellular vesicles (EVs) may reduce lung injury risks for ICU patients on mechanical ventilation, offering hope for improved recovery.
This news is pivotal as it introduces a potential breakthrough in treating ventilator-induced diaphragm dysfunction, a common and costly complication for ICU patients. By preserving muscle function and reducing weaning times, Leksum's research could significantly lower mortality rates, improve quality of life for millions, and alleviate the financial strain on healthcare systems worldwide.
